Claim your 20% discount on Global Market Reports with code ONLINE20. Limited time only.

What Is The Present And Forecasted Size Of The Hereditary Angioedema Market?

In the last few years, the hereditary angioedema market has witnessed a robust expansion. This sector is expected to surge from $2.62 billion in 2024 to $2.81 billion in 2025, with a compound annual growth rate (CAGR) of 7.4%. Factors contributing to the unprecedented growth during the historic period include the rising incidence of hereditary angioedema, enhanced investment in research and development, an increasing count of drug approvals, growth in product approval, along with augmenting disposable income.

Anticipated robust expansion is on the horizon for the hereditary angioedema market in the coming years. It’s projected to swell to a value of $3.84 billion by 2029, with a compound annual growth rate (CAGR) of 8.1%. Factors contributing to this growth during the forecast period include a rising prevalence of rare diseases, escalating healthcare spending, increased assistance from non-profit entities, heightened awareness of hereditary angioedema, and a focus on early diagnosis. Key market trends during this timeframe are likely to encompass technological advancements, the evolution of new treatments, the introduction of new medications, the implementation of advanced diagnostic resources, and progress in the field of genetic testing.

Get A Free Sample Of The Report:

https://www.thebusinessresearchcompany.com/sample.aspx?id=22002&type=smp

What Underlying Factors Are Supporting The Hereditary Angioedema Market Growth?

The increasing instances of rare diseases are forecasted to fuel the expansion of the hereditary angioedema market. Rare diseases, otherwise known as orphan diseases, are medical conditions that touch a minority of the populace. Advancements in medical research, shifts in population demographics, and environmental factors contribute to the uptick of these diseases. Hereditary angioedema (HAE) is a significant rare disease, underlining the importance of unique treatments and increased awareness due to the potentially fatal swelling episodes associated with it. The scarcity of the disease and its genetic component make early detection and focused therapies crucial for successful treatment and enhanced patient prognosis. For example, in June 2022, the Rare Disease Advisor revealed that hereditary angioedema (HAE) affects around 1 in 50,000 people, with estimated prevalence rates ranging between 1 in 10,000 and 1 in 150,000. Furthermore, HAE episodes lead to an estimated 15,000 to 30,000 emergency room visits each year in the United States. Hence, the rising instances of rare diseases are propelling the hereditary angioedema market’s growth.

How Does The Hereditary Angioedema Market Differ By Segment?

The hereditary angioedemamarket covered in this report is segmented –

1) By Type: Hereditary Angioedema Type I; Hereditary Angioedema Type II

2) By Treatment Type: Prophylaxis; On-demand

3) By Drug Class: C-1 Esterase Inhibitors; Bradykynin Receptor Antagonist; Kallikrein Inhibitors; Other Drug Classes

4) By Route Of Administration: Subcutaneous; Intravenous; Oral

5) By Distribution channel: Hospital Pharmacies; Retail Pharmacies; Online Pharmacies

Subsegments:

1) By Hereditary Angioedema Type I: C1-Inhibitor Deficiency; Low C1-Inhibitor Levels; Reduced C1-Inhibitor Function

2) By Hereditary Angioedema Type II: Normal C1-Inhibitor Levels; Dysfunctional C1-Inhibitor; Genetic Mutations In SERPING1 Gene

What Are The Dominant Trends Currently Seen In The Hereditary Angioedema Market?

In the hereditary angioedema market, leading companies are developing oral plasma kallikrein inhibitors to provide convenient and effective on-demand treatments. These drugs block plasma kallikrein to prevent excess bradykinin production, addressing hereditary angioedema. For instance, in September 2024, KalVista Pharmaceuticals, Inc., a US pharmaceutical firm, announced FDA acceptance of its new drug application for sebetralstat, an investigational oral plasma kallikrein inhibitor intended for on-demand treatment of hereditary angioedema attacks in patients aged 12 and above. This milestone moves the drug closer to potential approval and commercialization.

Who Are The Global Leaders Steering The Hereditary Angioedema Market Forward?

Major companies operating in the hereditary angioedema market are Intellia Therapeutics Inc., Sanofi S.A., Takeda Pharmaceutical Company Limited, Otsuka Pharmaceutical Co. Ltd., CSL Limited, Cipla Limited, BioMarin Pharmaceutical Inc., Ionis Pharmaceuticals Inc., BioCryst Pharmaceuticals Inc., Arrowhead Pharmaceuticals Inc., Spark Therapeutics Inc., Pharming Group N.V., Pharvaris N.V., Astria Therapeutics Inc., CENTOGENE N.V., KalVista Pharmaceuticals Inc., ADARx Pharmaceuticals Inc., Adverum Biotechnologies Inc., Attune Pharmaceuticals Inc., Lev Pharmaceuticals Inc.

Access The Complete Report Here:

https://www.thebusinessresearchcompany.com/report/hereditary-angioedema-global-market-report

Which Region Is Likely To Register The Fastest Growth In The Hereditary Angioedema Market?

North America was the largest region in the hereditary angioedema market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the hereditary angioedema market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Customize Your Report Here:

https://www.thebusinessresearchcompany.com/customise?id=22002&type=smp

Browse Through More Reports Similar to the Global Hereditary Angioedema Market 2025, By The Business Research Company

Hereditary Cancer Testing Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/hereditary-cancer-testing-global-market-report

Hereditary Angioedema Therapeutics Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/hereditary-angioedema-therapeutics-global-market-report

Hereditary Breast And Ovarian Cancer Syndrome Treatment Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/hereditary-breast-and-ovarian-cancer-syndrome-treatment-global-market-report

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model